Vaxxinity Inc (VAXX) Price & Analysis

Compare

140 Followers

VAXX Stock Chart & Stats

$0.02

$0.00(0.00%)

At close: Jan 08 4:00 PM EST

$0.02

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.00 - $0.05

Previous CloseN/A

Volume1.04K

Average Volume (3M)5.29K

Market Cap

$28.13K

Enterprise Value$12.77M

Total Cash (Recent Filing)$30.39M

Total Debt (Recent Filing)$15.17M

Price to Earnings (P/E)―

Beta318.30

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding126,784,680

10 Day Avg. Volume3,116

30 Day Avg. Volume5,294

Financial Highlights & Ratios

PEG Ratio18.90

Price to Book (P/B)8.02

Price to Sales (P/S)0.00

P/FCF Ratio-1.85

Enterprise Value/Market Cap454.03

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-7.82

Enterprise Value/Ebitda-0.24

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Innovative Vaccine PlatformVaxxinity's innovative platform for developing vaccines positions it well in the biotechnology sector, potentially transforming treatment landscapes for chronic diseases.

Strategic CollaborationsStrategic collaborations and partnerships can enhance Vaxxinity's market reach and provide essential funding, aiding in the development and commercialization of its products.

Cash PositionA strong cash position provides Vaxxinity with a liquidity cushion, allowing it to navigate financial challenges and invest in R&D for future growth.

Bears Say

High Financial LeverageHigh financial leverage can strain Vaxxinity's financial stability, increasing risk and potentially limiting its ability to invest in growth opportunities.

Lack Of Revenue GrowthThe absence of revenue growth and ongoing losses highlight challenges in monetizing products, which could hinder long-term sustainability and investor confidence.

Negative Cash FlowsNegative cash flows indicate operational inefficiencies and financial strain, potentially impacting Vaxxinity's ability to fund its R&D and operational activities.

Vaxxinity Inc News

Vaxxinity’s Parkinson’s candidate UB-312 demonstrates efficacy in publication

Vaxxinity announced that Nature Medicine has published exploratory data from the company’s Phase 1 clinical trial of UB-312...

2y ago

VAXX

Vaxxinity to voluntarily delist, deregister its Class A common stock

Vaxxinity announced its intention to voluntarily delist from the Nasdaq Global Market and to deregister its Class A...

2y ago

VAXX

VAXX Earnings this Week: How Will it Perform?

Vaxxinity Inc (VAXX) is scheduled to report 4th quarter earnings on 03/21/2024. Regarding Q4 estimates, Wall Street analysts...

2y ago

VAXX

Vaxxinity Inc Motivates Team with Option Repricing Initiative

The latest announcement is out from Vaxxinity Inc (VAXX). On March 8, 2024, Vaxxinity, Inc. implemented a significant...

2y ago

VAXX

Vaxxinity announces ‘positive’ target engagement data from Phase 1 trial

Vaxxinity announced “positive” clinical data from its UB-312 program in Parkinson’s disease, or PD, presented by Jean-Cosme Dodart,...

2y ago

VAXX

Vaxxinity Faces Nasdaq Delisting Over Share Price

Vaxxinity Inc (VAXX) has released an update. Vaxxinity, Inc. received notice from Nasdaq that its stock doesn’t meet...

2y ago

VAXX

Vaxxinity announces publication of data on VXX-401

Vaxxinity announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein...

2y ago

VAXX

Vaxxinity announces research collaboration with CTRND

Vaxxinity announced a research collaboration with the University of Florida’s Center for Translational Research in Neurodegenerative Disease, CTRND,...

2y ago

VAXX

Vaxxinity announces collaboration on space medicine research with UCF

Vaxxinity announced a collaboration with the University of Central Florida, UCF, to advance space medicine research. The research,...

2y ago

VAXX

Vaxxinity reports Q3 EPS (10c), consensus (12c)

“We continue to advance our clinical programs and to validate our platform with the goal of addressing major...

2y ago

VAXX

Baird starts Vaxxinity with Outperform, $7 price target

Baird initiated coverage of Vaxxinity with an Outperform rating and $7 price target. Vaxxinity is developing vaccines for...

2y ago

VAXX

Vaxxinity initiated with an Outperform at Baird

Baird initiated coverage of Vaxxinity with an Outperform rating and $7 price target. Published first on TheFly –...

2y ago

VAXX

Vaxxinity announces publication of Phase 2 trial of UB-311

Vaxxinity announced the print publication of Phase 2a clinical trial data in The Lancet’s eBioMedicine, stating that UB-311...

3y ago

VAXX

Vaxxinity Inc (VAXX) Q1 Earnings Cheat Sheet

Vaxxinity Inc (VAXX) is scheduled to report 1st quarter earnings on 05/08/2023. Regarding Q1 estimates, Wall Street analysts...

3y ago

VAXX

VAXX FAQ

What was Vaxxinity Inc’s price range in the past 12 months?

Vaxxinity Inc lowest stock price was $0.00 and its highest was $0.05 in the past 12 months.

What is Vaxxinity Inc’s market cap?

Vaxxinity Inc’s market cap is $28.13K.

When is Vaxxinity Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Vaxxinity Inc’s earnings last quarter?

Currently, no data Available

Is Vaxxinity Inc overvalued?

According to Wall Street analysts Vaxxinity Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vaxxinity Inc pay dividends?

Vaxxinity Inc does not currently pay dividends.

What is Vaxxinity Inc’s EPS estimate?

Vaxxinity Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Vaxxinity Inc have?

Vaxxinity Inc has 126,784,680 shares outstanding.

What happened to Vaxxinity Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Vaxxinity Inc?

Currently, no hedge funds are holding shares in VAXX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Vaxxinity Inc

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.